Raras
Buscar doenças, sintomas, genes...
Astrocitoma
ORPHA:94CID-10 · C71DOENÇA RARA

Um tumor que se desenvolve nas células de suporte (chamadas gliais) do cérebro ou da medula espinhal, e que apresenta características de astrócitos (um tipo de célula glial). Inclui os seguintes tipos: astrocitoma pilocítico, astrocitoma difuso, astrocitoma anaplásico, xantoastrocitoma pleomórfico, astrocitoma subependimário de células gigantes e glioblastoma.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um tumor que se desenvolve nas células de suporte (chamadas gliais) do cérebro ou da medula espinhal, e que apresenta características de astrócitos (um tipo de célula glial). Inclui os seguintes tipos: astrocitoma pilocítico, astrocitoma difuso, astrocitoma anaplásico, xantoastrocitoma pleomórfico, astrocitoma subependimário de células gigantes e glioblastoma.

Pesquisas ativas
13 ensaios
2243 total registrados no ClinicalTrials.gov
Publicações científicas
14.819 artigos
Último publicado: 2026 Apr 17
Medicamentos
11 registrados
CARMUSTINE, EVEROLIMUS, BEVACIZUMAB

Tem tratamento?

11 medicamentos registrados
Ver detalhes, fases e interações →
CARMUSTINEEVEROLIMUSBEVACIZUMABSELUMETINIBIMATINIB MESYLATEVINCRISTINE SULFATEVINCRISTINEIMATINIBSELUMETINIB SULFATEHYDROXYUREA

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
2.5
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C71
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
8 sintomas
🧠
Neurológico
3 sintomas
👁️
Olhos
2 sintomas
💪
Músculos
1 sintomas

+ 19 sintomas em outras categorias

Características mais comuns

Morfologia anormal do corpo caloso
Fraqueza muscular
Pituicitoma
Estradiol sérico diminuído
Hipopituitarismo
Anormalidade do nível circulante de adrenocorticotropina
33sintomas
Sem dados (33)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 33 características clínicas mais associadas, ordenadas por frequência.

Morfologia anormal do corpo calosoAbnormal corpus callosum morphology
Fraqueza muscularMuscle weakness
PituicitomaPituicytoma
Estradiol sérico diminuídoDecreased serum estradiol
HipopituitarismoHypopituitarism

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico14.819PubMed
Últimos 10 anos200publicações
Pico2026122 papers
Linha do tempo
2026Hoje · 2026🧪 1979Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

20 genes identificados com associação a esta condição.

SRGAP3SLIT-ROBO Rho GTPase-activating protein 3Candidate gene tested inAltamente restrito
FUNÇÃO

GTPase-activating protein for RAC1 and perhaps Cdc42, but not for RhoA small GTPase. May attenuate RAC1 signaling in neurons

LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
Inactivation of CDC42 and RAC1RAC1 GTPase cycleCDC42 GTPase cycle
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
54.4 TPM
Cérebro - Hemisfério cerebelar
50.9 TPM
Córtex cerebral
19.1 TPM
Brain Frontal Cortex BA9
18.9 TPM
Brain Anterior cingulate cortex BA24
11.8 TPM
OUTRAS DOENÇAS (1)
pilomyxoid astrocytoma
HGNC:19744UniProt:O43295
EGFREpidermal growth factor receptorCandidate gene tested inRestrito
FUNÇÃO

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:10805725, PubMed:27153536, PubMed:2790960, PubMed:35538033). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, PubMed:7679104, PubMed:8144591, PubM

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneGolgi apparatus membraneNucleus membraneEndosomeEndosome membraneNucleusSecreted

VIAS BIOLÓGICAS (10)
Signaling by EGFRInhibition of Signaling by Overexpressed EGFRSignaling by ERBB2Signaling by ERBB4Signaling by ERBB2 TMD/JMD mutants
MECANISMO DE DOENÇA

Lung cancer

A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
78.3 TPM
Skin Not Sun Exposed Suprapubic
75.9 TPM
Fibroblastos
60.6 TPM
Nervo tibial
43.1 TPM
Vagina
40.6 TPM
OUTRAS DOENÇAS (4)
inflammatory skin and bowel disease, neonatal, 2lung cancergliosarcomagiant cell glioblastoma
HGNC:3236UniProt:P00533
LZTR1Leucine-zipper-like transcriptional regulator 1Candidate gene tested inTolerante
FUNÇÃO

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras (K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) (PubMed:30442762, PubMed:30442766, PubMed:30481304). Is a negative regulator of RAS-MAPK signaling that acts by controlling Ras levels and decreasing Ras association with membranes (PubMed:30442762, PubMed:30442766, PubMed:30481304)

LOCALIZAÇÃO

Endomembrane systemRecycling endosomeGolgi apparatus

MECANISMO DE DOENÇA

Glioma

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
76.5 TPM
Nervo tibial
68.8 TPM
Útero
67.8 TPM
Cervix Ectocervix
65.1 TPM
Cervix Endocervix
61.7 TPM
OUTRAS DOENÇAS (9)
Noonan syndrome 10RASopathyNoonan syndrome 2cafe au lait spots, multiple
HGNC:6742UniProt:Q8N653
ROS1Proto-oncogene tyrosine-protein kinase ROSCandidate gene tested inTolerante
FUNÇÃO

Receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. NELL2 is an endogenous ligand for ROS1. Upon endogenous stimulation by NELL2, ROS1 activates the intracellular signaling pathway and triggers epididymal epithelial differentiation and subsequent sperm maturation (By similarity). May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including

LOCALIZAÇÃO

Cell membrane

EXPRESSÃO TECIDUAL(Tecido-específico)
Pulmão
11.1 TPM
Fibroblastos
3.0 TPM
Testículo
1.0 TPM
Córtex cerebral
0.8 TPM
Brain Frontal Cortex BA9
0.8 TPM
OUTRAS DOENÇAS (2)
cholangiocarcinomagiant cell glioblastoma
HGNC:10261UniProt:P08922
BRAFSerine/threonine-protein kinase B-rafCandidate gene tested inAltamente restrito
FUNÇÃO

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
PPARGPeroxisome proliferator-activated receptor gammaCandidate gene tested inModerado
FUNÇÃO

Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481). Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metab

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (7)
Regulation of PTEN gene transcriptionTranscriptional regulation of white adipocyte differentiationPPARA activates gene expressionMECP2 regulates transcription factorsNuclear Receptor transcription pathway
EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
111.2 TPM
Adipose Visceral Omentum
100.8 TPM
Mama
71.3 TPM
Cólon transverso
21.6 TPM
Fibroblastos
20.4 TPM
OUTRAS DOENÇAS (6)
type 2 diabetes mellitusPPARG-related familial partial lipodystrophyinherited obesitygliosarcoma
HGNC:9236UniProt:P37231
KIAA1549UPF0606 protein KIAA1549Candidate gene tested inRestrito
FUNÇÃO

May play a role in photoreceptor function

LOCALIZAÇÃO

MembraneCell projection, cilium

VIAS BIOLÓGICAS (1)
Signaling by BRAF and RAF1 fusions
MECANISMO DE DOENÇA

Retinitis pigmentosa 86

A form of retinitis pigmentosa, a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP86 is an autosomal recessive form.

EXPRESSÃO TECIDUAL(Baixa expressão)
Brain Frontal Cortex BA9
5.0 TPM
Córtex cerebral
4.9 TPM
Útero
3.9 TPM
Pituitária
3.6 TPM
Glândula salivar
3.5 TPM
OUTRAS DOENÇAS (3)
retinitis pigmentosa 86pilomyxoid astrocytomaretinitis pigmentosa
HGNC:22219UniProt:Q9HCM3
IDH2Isocitrate dehydrogenase [NADP], mitochondrialCandidate gene tested inAltamente restrito
FUNÇÃO

Plays a role in intermediary metabolism and energy production (PubMed:19228619, PubMed:22416140). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed:19228619, PubMed:22416140)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (4)
Citric acid cycle (TCA cycle)Maturation of TCA enzymes and regulation of TCA cycleMitochondrial protein degradationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

D-2-hydroxyglutaric aciduria 2

A neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
442.8 TPM
Coração - Ventrículo esquerdo
311.5 TPM
Rim - Medula
273.8 TPM
Linfócitos
186.0 TPM
Fígado
184.7 TPM
OUTRAS DOENÇAS (13)
d-2-hydroxyglutaric aciduria 2anaplastic oligodendrogliomagemistocytic astrocytomaoligoastrocytoma
HGNC:5383UniProt:P48735
NTRK2BDNF/NT-3 growth factors receptorCandidate gene tested inAltamente restrito
FUNÇÃO

Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity (By similarity). Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2 (PubMed:15494731, PubM

LOCALIZAÇÃO

Cell membraneEndosome membraneEarly endosome membraneCell projection, axonCell projection, dendriteCytoplasm, perinuclear regionPostsynaptic density

VIAS BIOLÓGICAS (4)
NTF4 activates NTRK2 (TRKB) signalingBDNF activates NTRK2 (TRKB) signalingNTF3 activates NTRK2 (TRKB) signalingActivated NTRK2 signals through FYN
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 58

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE58 is an autosomal dominant condition characterized by onset of refractory seizures in the first days or months of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Anterior cingulate cortex BA24
79.5 TPM
Brain Frontal Cortex BA9
75.0 TPM
Córtex cerebral
74.2 TPM
Brain Caudate basal ganglia
73.0 TPM
Cérebro - Amígdala
73.0 TPM
OUTRAS DOENÇAS (5)
developmental and epileptic encephalopathy, 58obesity, hyperphagia, and developmental delaypilomyxoid astrocytomaearly-onset obesity-hyperphagia-severe developmental delay syndrome
HGNC:8032UniProt:Q16620
IDH1Isocitrate dehydrogenase [NADP] cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase (PubMed:10521434, PubMed:19935646). Plays a critical role in the generation of NADPH, an important cofactor in many biosynthesis pathways (PubMed:10521434). May act as a corneal epithelial crystallin and may be involved in maintaining corneal epithelial transparency (By similarity)

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome

VIAS BIOLÓGICAS (3)
NADPH regenerationNFE2L2 regulating TCA cycle genesPeroxisomal protein import
MECANISMO DE DOENÇA

Glioma

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
266.5 TPM
Fígado
100.4 TPM
Esôfago - Mucosa
99.8 TPM
Tecido adiposo
81.8 TPM
Próstata
77.7 TPM
OUTRAS DOENÇAS (7)
Maffucci syndromemetaphyseal chondromatosis with D-2-hydroxyglutaric aciduriaacute myeloid leukemia with multilineage dysplasiaOllier disease
HGNC:5382UniProt:O75874
MGMTMethylated-DNA--protein-cysteine methyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
MGMT-mediated DNA damage reversal
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
38.0 TPM
Testículo
25.7 TPM
Tecido adiposo
25.1 TPM
Mama
24.2 TPM
Bladder
23.6 TPM
OUTRAS DOENÇAS (3)
gliosarcomafamilial melanomagiant cell glioblastoma
HGNC:7059UniProt:P16455
KRASGTPase KRasCandidate gene tested inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621, PubMed:39809765). Plays an important role in the regulation of cell proliferation (PubMed:22711838, PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation and ultimately degradation of GJA1 (By similarity). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306)

LOCALIZAÇÃO

Cell membraneEndomembrane systemCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsRUNX3 regulates p14-ARF
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
30.7 TPM
Cérebro - Hemisfério cerebelar
25.1 TPM
Esôfago - Muscular
22.2 TPM
Esôfago - Mucosa
21.6 TPM
Esôfago - Junção
20.2 TPM
OUTRAS DOENÇAS (20)
gastric canceracute myeloid leukemialinear nevus sebaceous syndromeNoonan syndrome 3
HGNC:6407UniProt:P01116
NFKBIANF-kappa-B inhibitor alphaCandidate gene tested inAltamente restrito
FUNÇÃO

Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localization signals (PubMed:1493333, PubMed:36651806, PubMed:7479976). On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription (PubMed:7479976, PubMed:7628694, PubMed:7796813, PubMed:7878466)

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
RIP-mediated NFkB activation via ZBP1TRAF6 mediated NF-kB activationTAK1-dependent IKK and NF-kappa-B activation NF-kB is activated and signals survivalCLEC7A (Dectin-1) signaling
MECANISMO DE DOENÇA

Ectodermal dysplasia and immunodeficiency 2

A form of ectoderma dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. This form of ectodermal dysplasia is associated with decreased production of pro-inflammatory cytokines and certain interferons, rendering patients susceptible to infection. EDAID2 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
497.5 TPM
Nervo tibial
450.8 TPM
Baço
352.8 TPM
Ovário
332.9 TPM
Skin Not Sun Exposed Suprapubic
320.1 TPM
OUTRAS DOENÇAS (5)
ectodermal dysplasia and immunodeficiency 2ectodermal dysplasia and immune deficiencygiant cell glioblastomanasopharyngeal carcinoma
HGNC:7797UniProt:P25963
TP53Cellular tumor antigen p53Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
RAF1RAF proto-oncogene serine/threonine-protein kinaseCandidate gene tested inAltamente restrito
FUNÇÃO

Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and

LOCALIZAÇÃO

CytoplasmCell membraneMitochondrionNucleus

VIAS BIOLÓGICAS (5)
IFNG signaling activates MAPKsCD209 (DC-SIGN) signalingStimuli-sensing channelsGP1b-IX-V activation signallingRap1 signalling
MECANISMO DE DOENÇA

Noonan syndrome 5

A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
152.2 TPM
Artéria tibial
139.4 TPM
Cérebro - Hemisfério cerebelar
134.9 TPM
Sangue
131.1 TPM
Ovário
129.4 TPM
OUTRAS DOENÇAS (9)
Noonan syndrome 5LEOPARD syndrome 2dilated cardiomyopathy 1NNNoonan syndrome
HGNC:9829UniProt:P04049
TACC3Transforming acidic coiled-coil-containing protein 3Candidate gene tested inTolerante
FUNÇÃO

Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome. Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors (By similarity). Acts as a component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter-microtubule bridge. The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fiber tension (P

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, spindle pole

VIAS BIOLÓGICAS (2)
Negative regulation of NOTCH4 signalingNOTCH3 Activation and Transmission of Signal to the Nucleus
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
122.0 TPM
Linfócitos
98.8 TPM
Sangue
80.8 TPM
Baço
44.0 TPM
Fibroblastos
29.4 TPM
OUTRAS DOENÇAS (2)
giant cell glioblastomagliosarcoma
HGNC:11524UniProt:Q9Y6A5
SEPTIN14Septin-14Candidate gene tested inTolerante
FUNÇÃO

Filament-forming cytoskeletal GTPase (Probable). Involved in the migration of cortical neurons and the formation of neuron leading processes during embryonic development (By similarity). Plays a role in sperm head formation during spermiogenesis, potentially via facilitating localization of ACTN4 to cell filaments (PubMed:33228246)

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeletonCell projection, axonCell projection, dendritePerikaryonCytoplasm, perinuclear regionCytoplasmic vesicle, secretory vesicle, acrosome

OUTRAS DOENÇAS (2)
gliosarcomagiant cell glioblastoma
HGNC:33280UniProt:Q6ZU15
FGFR3Fibroblast growth factor receptor 3Candidate gene tested inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferat

LOCALIZAÇÃO

Cell membraneCytoplasmic vesicleEndoplasmic reticulumSecreted

VIAS BIOLÓGICAS (2)
Signaling by FGFR3 in diseaset(4;14) translocations of FGFR3
MECANISMO DE DOENÇA

Achondroplasia

A frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands. ACH is an autosomal dominant disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
364.6 TPM
Skin Sun Exposed Lower leg
356.5 TPM
Esôfago - Mucosa
199.7 TPM
Brain Caudate basal ganglia
148.4 TPM
Brain Nucleus accumbens basal ganglia
135.4 TPM
OUTRAS DOENÇAS (19)
nevus, epidermalsevere achondroplasia-developmental delay-acanthosis nigricans syndromelacrimoauriculodentodigital syndrome 2testicular germ cell tumor
HGNC:3690UniProt:P22607
FGFR1Fibroblast growth factor receptor 1Candidate gene tested inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activati

LOCALIZAÇÃO

Cell membraneNucleusCytoplasm, cytosolCytoplasmic vesicle

VIAS BIOLÓGICAS (2)
Epithelial-Mesenchymal Transition (EMT) during gastrulationFormation of paraxial mesoderm
MECANISMO DE DOENÇA

Pfeiffer syndrome

A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
144.8 TPM
Ovário
142.9 TPM
Artéria tibial
134.1 TPM
Fallopian Tube
122.3 TPM
Cérebro - Hemisfério cerebelar
122.0 TPM
OUTRAS DOENÇAS (20)
Hartsfield-Bixler-Demyer syndromeencephalocraniocutaneous lipomatosisosteoglophonic dysplasiaPfeiffer syndrome
HGNC:3688UniProt:P11362
TACC1Transforming acidic coiled-coil-containing protein 1Candidate gene tested inTolerante
FUNÇÃO

Involved in transcription regulation induced by nuclear receptors, including in T3 thyroid hormone and all-trans retinoic acid pathways (PubMed:20078863). Might promote the nuclear localization of the receptors (PubMed:20078863). Likely involved in the processes that promote cell division prior to the formation of differentiated tissues

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosomeMidbodyMembrane

VIAS BIOLÓGICAS (1)
Signaling by plasma membrane FGFR1 fusions
EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
142.9 TPM
Esôfago - Muscular
140.6 TPM
Útero
124.4 TPM
Esôfago - Junção
122.5 TPM
Tecido adiposo
119.2 TPM
OUTRAS DOENÇAS (2)
giant cell glioblastomagliosarcoma
HGNC:11522UniProt:O75410

Medicamentos e terapias

CARMUSTINEPhase 4

Mecanismo: Glutathione reductase inhibitor

EVEROLIMUSPhase 4

Mecanismo: FK506-binding protein 1A inhibitor

BEVACIZUMABPhase 4

Mecanismo: Vascular endothelial growth factor A inhibitor

SELUMETINIBPhase 3

Mecanismo: Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor

IMATINIB MESYLATEPhase 3

Mecanismo: Tyrosine-protein kinase ABL inhibitor

VINCRISTINE SULFATEPhase 3

Mecanismo: Tubulin inhibitor

VINCRISTINEPhase 3

Mecanismo: Tubulin inhibitor

IMATINIBPhase 3

Mecanismo: Tyrosine-protein kinase ABL inhibitor

SELUMETINIB SULFATEPhase 3

Mecanismo: Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor

HYDROXYUREAPhase 3

Mecanismo: Ribonucleoside-diphosphate reductase RR1 inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

1,975 variantes patogênicas registradas no ClinVar.

🧬 SRGAP3: GRCh37/hg19 3p26.3-14.3(chr3:2263690-55016039)x3 ()
🧬 SRGAP3: NM_014850.4(SRGAP3):c.448C>T (p.His150Tyr) ()
🧬 SRGAP3: GRCh37/hg19 3p26.3-25.3(chr3:61892-10562002)x1 ()
🧬 SRGAP3: GRCh37/hg19 3p26.3-22.3(chr3:60000-34461438)x3 ()
🧬 SRGAP3: GRCh37/hg19 3p26.3-22.3(chr3:61891-33946644)x3 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 13 variantes classificadas pelo ClinVar.

13
VUS (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
RAD54L: NM_003579.4(RAD54L):c.1759C>T (p.Arg587Trp) [Uncertain significance]
RAD52: NM_134424.4(RAD52):c.84+1G>A [Uncertain significance]
FGFR1: NM_023110.3(FGFR1):c.1968G>T (p.Lys656Asn) []
FGFR1: NM_023110.3(FGFR1):c.1913A>G (p.Lys638Arg) []
FGFR1: NM_023110.3(FGFR1):c.1966_1968delinsGAC (p.Lys656Asp) []

Vias biológicas (Reactome)

177 vias biológicas associadas aos genes desta condição.

Inactivation of CDC42 and RAC1 CDC42 GTPase cycle RAC1 GTPase cycle Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus alectinib sensitve ALK mutants ceritinib-resistant ALK mutants ceritinib-resistant ALK mutants don't bind ceritinib ALK mutants bind type I TKIs Spry regulation of FGF signaling Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Regulation of PTEN gene transcription MECP2 regulates transcription factors MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Transcriptional activation of mitochondrial biogenesis Citric acid cycle (TCA cycle) Mitochondrial protein degradation Maturation of TCA enzymes and regulation of TCA cycle NGF-independant TRKA activation BDNF activates NTRK2 (TRKB) signaling NTF3 activates NTRK2 (TRKB) signaling NTF4 activates NTRK2 (TRKB) signaling Activated NTRK2 signals through RAS Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PI3K Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FYN NTRK2 activates RAC1 Activated NTRK2 signals through CDK5 Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate NADPH regeneration Neutrophil degranulation Peroxisomal protein import NFE2L2 regulating TCA cycle genes MGMT-mediated DNA damage reversal SOS-mediated signalling Activation of RAS in B cells SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events Downstream signal transduction Tie2 Signaling DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ca2+ pathway Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling NF-kB is activated and signals survival FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation SUMOylation of immune response proteins IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling Ub-specific processing proteases Interleukin-1 signaling TRAF6 mediated NF-kB activation SARS-CoV-1 activates/modulates innate immune responses Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Dengue virus modulates apoptosis Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation Stimuli-sensing channels Rap1 signalling GP1b-IX-V activation signalling IFNG signaling activates MAPKs Negative regulation of NOTCH4 signaling PI3K Cascade Signaling by activated point mutants of FGFR3 FGFR3b ligand binding and activation FGFR3c ligand binding and activation t(4;14) translocations of FGFR3 Phospholipase C-mediated cascade; FGFR3 PI-3K cascade:FGFR3 Negative regulation of FGFR3 signaling Signaling by FGFR3 in disease Signaling by FGFR3 fusions in cancer Signaling by FGFR1 amplification mutants Signaling by activated point mutants of FGFR1 FGFR1b ligand binding and activation FGFR1c ligand binding and activation FGFR1c and Klotho ligand binding and activation Phospholipase C-mediated cascade: FGFR1 Downstream signaling of activated FGFR1 PI-3K cascade:FGFR1 Negative regulation of FGFR1 signaling Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado3
3Fase 39
2Fase 27
1Fase 15
Medicamentos catalogadosEnsaios clínicos· 10 medicamentos · 14 ensaios
✓ Aprovados — podem ser usados hoje
CARMUSTINEEVEROLIMUSBEVACIZUMAB
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Astrocitoma

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

4 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

2.243 ensaios clínicos encontrados, 13 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
5.302 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 5.302

#1

TERT Promoter Methylation in Glioblastoma and its Paradoxical Association with Upregulated Gene Expression.

Neurology India2026 Mar 01

Este estudo demonstra que, em glioblastomas (uma forma agressiva de astrocitoma), o gene TERT, fundamental para a proliferação do tumor, exibe uma hipermetilação em seu promotor. De forma paradoxal, essa alteração epigenética não silencia o gene, mas sim aumenta sua expressão, impulsionando a patologia da doença. Os achados sugerem que agentes desmetilantes podem ser uma importante estratégia terapêutica para inibir a atividade do TERT e, consequentemente, o crescimento das células cancerígenas.

🇧🇷 traduzido
#2

High-Grade Astrocytoma With Piloid Features: An Aggressive Clinicogenomic Entity Distinct From Pilocytic Astrocytoma.

Journal of Korean medical science2026 Mar 09

Este estudo identifica o Astrocitoma de Alto Grau com Características Pilóides (HGAP) como uma nova entidade clinicogenômica agressiva, claramente distinta do Astrocitoma Pilocítico (AP) pediátrico e adulto. Para pacientes e médicos, é crucial saber que o HGAP afeta predominantemente adultos, possui perfis genéticos únicos (como deleções CDKN2A/B e mutações NF1/ATRX) e está associado a uma sobrevida significativamente mais curta em comparação com o AP, que geralmente tem um prognóstico mais favorável. Esta distinção ressalta a importância da análise molecular precisa para um diagnóstico correto, orientação prognóstica e para o desenvolvimento de estratégias terapêuticas mais eficazes.

🇧🇷 traduzido
#3

Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.

Journal of neuropathology and experimental neurology2026 Mar 09

Em gliomas difusos do tipo adulto, a perda de genes CDKN2A/B e MTAP frequentemente ocorre em conjunto, levantando a possibilidade de que o teste de MTAP por imuno-histoquímica (IHC) pudesse indicar o status de CDKN2A/B. No entanto, este estudo revela que, embora a perda de um exemplar de ambos os genes seja comum, a perda completa de CDKN2A/B nem sempre significa a perda completa de MTAP devido a diferentes mecanismos genéticos. Isso significa que o teste de MTAP por IHC não é um substituto totalmente confiável para determinar o status de CDKN2A/B em todos os casos, e a avaliação genômica direta pode ser necessária para uma compreensão precisa e decisões clínicas.

🇧🇷 traduzido
#4

Central Precocious Puberty and Optic Pathway Glioma in Children with Neurofibromatosis 1: Associations with Tumor Location, Vision, and Treatment.

The Journal of pediatrics2026 Mar 02

Em crianças com Neurofibromatose 1 (NF1) e gliomas das vias ópticas (GVOs), pode ocorrer puberdade precoce central (PPC). Este estudo demonstrou que a PPC nesses pacientes está associada a tumores localizados no hipotálamo, uma visão mais comprometida e uma maior probabilidade de o GVO precisar de tratamento. Para pacientes e médicos, isso significa que a PPC é um importante sinal que indica a necessidade de uma avaliação cuidadosa da localização do tumor, do estado da visão e da possível urgência de intervenção terapêutica.

🇧🇷 traduzido
#5

Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.

Nature communications2026 Feb 26

Este estudo avaliou uma nova estratégia para o astrocitoma de alto grau recorrente, uma doença de difícil tratamento, combinando a terapia térmica intersticial a laser (LITT) com o imunoterápico pembrolizumab, já que imunoterapias sozinhas mostram pouca eficácia. Os resultados foram muito positivos, com a combinação LITT + pembrolizumab melhorando significativamente a sobrevida global (mediana de 11.8 vs 5.2 meses) e a sobrevida livre de progressão em comparação com a cirurgia sem LITT, levando inclusive à interrupção precoce do estudo por benefício. A terapia foi bem tolerada e sugere que a LITT pode "preparar" o tumor, ativando o sistema imune para que o pembrolizumab seja mais eficaz, oferecendo uma nova e promissora opção para pacientes e médicos.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC4.802 artigos no totalmostrando 199

2026

A 57-year-old male with diffuse astrocytoma in the lateral ventricle: case report.

BMC neurology
2026

Nested pediatric low-grade glioma cerebral organoid avatars reveal glutamatergic neuron stromal growth dependency.

Genes &amp; development
2026

The Causal Role of Circulating Inflammatory Cytokines in Brain Tumors: Insights from Genetic Epidemiology.

Immunological investigations
2026

Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies.

Journal of immunotherapy and precision oncology
2026

Is maternal smoking during pregnancy associated with childhood brain tumors? A systematic literature review.

Toxicology letters
2026

Stereotactic radiosurgery for pilocytic astrocytoma: A single center retrospective study.

Neurosurgical review
2026

Pilocytic astrocytoma surgery via the pineal region in a 9-year-old boy via the infratentorial-supracerebellar approach.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

Case Report: Molecular diagnostics and clinical courses of two adult spinal pilocytic astrocytoma long-term survivors with GTF2I::BRAF fusion.

Frontiers in oncology
2026

T2-FLAIR mismatch sign in nonenhancing astrocytoma, IDH-mutant: impact of tumor area on diagnostic sensitivity.

Journal of neuro-oncology
2026

Identification of BRAF V600E Mutation in Cerebrospinal Fluid Aids in Diagnosing Leptomeningeal Carcinomatosis Arising From Pleomorphic Xanthoastrocytoma: A Case Report.

Cancer reports (Hoboken, N.J.)
2026

Impact of corticosteroid administration on glioblastoma progression before and after adjuvant treatments: recent updates on contradictory findings and mechanistic interactions.

Frontiers in oncology
2026

PD-L1 Expression in Gliomas: A Potential Immunotherapeutic Target in High-grade Tumours.

Prague medical report
2026

Prognostic significance of CDKN2A/B hemizygous deletion in IDH-mutant astrocytomas: a systematic review and meta-analysis.

Brain tumor pathology
2026

Thoracic intramedullary spinal cord astrocytoma associated with syringomyelia: a case report of gross total resection.

International journal of surgery case reports
2026

FGFR1:TACC1-Fused Pilocytic Astrocytoma in a Child With Muenke Syndrome: A Case Report.

Pediatric blood &amp; cancer
2026

Alexander disease mutations differentially sensitize glial fibrillary acidic protein (GFAP) to posttranslational modifications and network disruption by oxidants.

Redox biology
2026

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

European journal of cancer (Oxford, England : 1990)
2026

Exploiting Metabolic Dependencies for Therapeutic Targeting of Brain Cancers.

Cancer letters
2026

Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.

Cancer communications (London, England)
2026

TERT Promoter Methylation in Glioblastoma and its Paradoxical Association with Upregulated Gene Expression.

Neurology India
2026

Prognostic relevance of resection at first recurrence in isocitrate dehydrogenase mutant lower-grade glioma: results from a retrospective, single-center, volumetric analysis.

Journal of neuro-oncology
2026

Identifying clinically relevant cell state interactions in the tumor microenvironment of IDH-mutant gliomas using CSI-TME.

Molecular systems biology
2026

High-Grade Astrocytoma With Piloid Features: An Aggressive Clinicogenomic Entity Distinct From Pilocytic Astrocytoma.

Journal of Korean medical science
2026

Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.

Journal of neuropathology and experimental neurology
2026

High-grade gliomas and Lynch syndrome: A retrospective descriptive study with a literature review.

Neuro-oncology practice
2026

Tele-cognitive rehabilitation for adult lower-grade glioma: An interim prospective pilot feasibility study.

Neuro-oncology practice
2026

Differentiating medulloblastoma and pilocytic astrocytoma in children based on multimodal MRI radiomics model.

Neuroradiology
2026

PTPN11-related Noonan syndrome predisposes to multifocal low-grade CNS tumors harboring FGFR1 variants.

Journal of neuro-oncology
2026

Clinicopathologic, molecular and tumor immune microenvironment features of mismatch repair-deficient glioblastomas in Lynch syndrome: a multicenter study of 29 cases with therapeutic implications.

Acta neuropathologica communications
2026

Central Precocious Puberty and Optic Pathway Glioma in Children with Neurofibromatosis 1: Associations with Tumor Location, Vision, and Treatment.

The Journal of pediatrics
2025

Primary Pediatric Brain Tumors in a Tertiary Referral Center in Iran: A 13-Year Retrospective Analysis.

Archives of Iranian medicine
2026

Seizure Presentation of a Grade II Astrocytoma in a Patient With Ollier's Disease: A Case Report and Brief Review.

Cureus
2026

A multifocal IDH-mutant glioma with differential response to IDH inhibition: Role of quantitative neuroimaging.

Radiology case reports
2026

Nuclear and membrane-bound hormone receptors in glioblastoma: Expression, functionality, and therapeutic implications.

Neuro-oncology advances
2026

Multifocal cerebral and orbital neoplastic lesions in a 2-year-old child: a case report and literature review emphasizing diagnostic uncertainty and ethical decision-making.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma.

Neuro-oncology
2026

Proteomics in IDH-mutated diffuse lower-grade glioma: a scoping review.

Neuro-oncology advances
2026

A Systematic Review and Meta-Analysis of Executive Function Outcomes in Pediatric Central Nervous System Tumor Survivors.

Actas espanolas de psiquiatria
2026

Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.

Nature communications
2026

An Evaluation Study of PET Image Quality Factors in Brain Tumor Diagnosis.

Tomography (Ann Arbor, Mich.)
2026

Pediatric Pilocytic Astrocytoma, Rich in Oligodendrocyte-Like Cells: A Diagnostic Challenge.

Journal of pediatric hematology/oncology
2026

A Case of IDH-Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant.

Neuropathology : official journal of the Japanese Society of Neuropathology
2026

Fluid Suppression Techniques Combined With Amide Proton Transfer-Weighted Imaging for the Evaluation of Adult-Type Diffuse Gliomas.

Korean journal of radiology
2026

Management of glioblastoma intramedullary spinal cord metastasis with advanced intraoperative techniques: a case series and systematic review.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2026

The expression pattern and prognostic relevance of p120-catenin, COL4A2 and SOX10 in glioma.

Frontiers in oncology
2026

Single-cell RNA sequencing suggests different progenitor lineages between IDH mutant and IDHwt glioma.

Neuro-oncology advances
2026

Placental small extracellular vesicles as modulators of bisphenol A-induced oxidative stress and mitochondrial activation in human astrocytoma cells (U-373 MG).

American journal of physiology. Cell physiology
2026

Cross face nerve grafting for reinnervation of nasal and tongue mucosa following trigeminal nerve injury.

JPRAS open
2026

Surgical Management of Optic Pathway-Hypothalamic Gliomas: Institutional Experience and Systematic Review.

Operative neurosurgery (Hagerstown, Md.)
2026

CATNON conclusion: Closure on Concurrent Chemotherapy in IDHmt Grade 3 Astrocytoma.

Neuro-oncology
2026

RCBVmax from DSC Perfusion MRI as a Supportive Imaging Biomarker for Differentiating IDH-Mutant Astrocytomas and Oligodendroglioma.

Clinical neuroradiology
2026

Transfer Learning Strategies for Pathological Foundation Models: A Systematic Evaluation in Brain Tumor Classification.

Pathology international
2026

Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case.

Journal of neurosurgery. Case lessons
2025

Clinical profiles of tuberous sclerosis complex: A regionally based survey.

Brain &amp; development
2026

Pilocytic astrocytoma in pediatric and adult patients: a single-center analysis of 650 cases.

Virchows Archiv : an international journal of pathology
2026

Spontaneous contrast enhancement fluctuation in adult pilocytic astrocytoma.

Radiologia
2026

Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.

Journal of neuropathology and experimental neurology
2026

18F-DOPA PET Silence in High-grade Glioma Subtype F: A Distinct Metabolic Phenotype.

Clinical nuclear medicine
2026

Redundancy in Growth Factor Receptor Signaling in Adult Astrocytoma Resistance to Small-Molecule Tyrosine Kinase Inhibitors.

International journal of molecular sciences
2026

Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.

Acta neuropathologica
2026

Impact of prenatal sirolimus on cardiac rhabdomyomas and brain tubers.

Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
2026

Synchronous diagnosis of multicentric glioma with distinct isocitrate dehydrogenase molecular profiles: a case report.

CNS oncology
2026

[Overall survival prediction scale for patients with grade 4 brain astrocytoma].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2026

Fourth ventricular pilocytic astrocytoma mimicking an arachnoid cyst: A case report and review of literature.

Surgical neurology international
2026

Eloquent glioma resection assisted by brain connectomics: A new tool for awake neurosurgery.

Surgical neurology international
2026

A case report on the diagnosis and treatment of a glioneuronal tumor with ATRX alteration, kinase fusion, and anaplastic features.

Frontiers in oncology
2026

Case Report: Novel ASAP1::BRAF fusion in a young adult with low-grade temporal lobe glioma.

Frontiers in oncology
2026

Clinical predictors of overall survival in pediatric patients with intramedullary spinal tumors: an analysis of the SEER database.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

The Utility of Cystathionine Assessment using proton MR Spectroscopy for the Preoperative Differential Diagnosis of Adult-Type Diffuse Gliomas.

AJNR. American journal of neuroradiology
2026

A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research
2026

Magnetic resonance imaging findings of dysembryoplastic neuroepithelial tumors and low-grade astrocytomas.

Journal of the Chinese Medical Association : JCMA
2026

Extracellular vesicles-mediated communication between glioblastoma and astrocytes promotes pro-tumorigenic activation.

Medical oncology (Northwood, London, England)
2025

The Role of b-value Diffusion-weighted Imaging in Differentiating High-grade and Low-grade Brain Tumors: A Comprehensive Study with Standard b-value DWI.

Advanced biomedical research
2026

Neuro-Ophthalmic Manifestations of Suprasellar Pilomyxoid Astrocytoma.

Neuro-ophthalmology (Aeolus Press)
2025

Heterogeneous DNA methylation and gene expression patterns underly metabolic plasticity in canine astrocytoma-derived stem-like cells.

Frontiers in oncology
2025

Emerging minimally invasive laser and light-based therapies for glioblastoma: a systematic review.

Frontiers in oncology
2026

Integrated Molecular Diagnosis Paving the Way for Therapeutic Success in Recurrent Astrocytoma Treatment.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2026

18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research
2025

Recurrent distal ventriculoperitoneal shunt migration in an obese patient with high-grade glioma: A case report.

Surgical neurology international
2026

Pediatric intramedullary spinal tumors: Pathological and clinical outcomes in a 96-case single-institution cohort study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.

European journal of nuclear medicine and molecular imaging
2026

Association of a diffuse phenotype on MRI with shorter overall survival in patients with astrocytoma CNS WHO grades 2 and 3.

Journal of neurosurgery
2026

Stroke-Like Migraine Attacks After Radiation Therapy (SMART) Syndrome: A Case Report and Review of a Rare Delayed Complication of Cranial Irradiation.

Clinical case reports
2026

Retrospective Analysis of Epidemiology of Intracranial and Spinal Tumor in North Western Part of India: 5-Year Observational Study of 1315 Cases.

Cureus
2026

Discovery of the MELK-Nucleostemin Axis in Glioblastoma: Implications for p53 Regulation and Tumor Progression.

Journal of microbiology and biotechnology
2026

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.

Journal of neuro-oncology
2025

Leveraging transcriptomic, DNA methylation, and molecular alteration data to optimize the classification of IDH-mutant gliomas for therapy selection.

Frontiers in oncology
2025

Anti-Neuroinflammatory Potential of Drospirenone in A TLR4-Driven In Vitro Model of Neuropathic Pain.

Cell journal
2026

Current Pharmacotherapeutic Strategies in Diffuse Gliomas: Focus on Glioblastoma, IDH-Wildtype, and Emerging Targeted Therapies for IDH-Mutant Tumors.

Pharmaceuticals (Basel, Switzerland)
2026

From Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection.

International journal of molecular sciences
2026

Malignant Progression of Subependymal Giant Cell Astrocytoma-Imitating Fibrous Meningioma in a Child Carrying a Germline <italic>CHEK2</italic> Mutation.

Pathobiology : journal of immunopathology, molecular and cellular biology
2026

Pediatric low-grade epilepsy-associated tumors (LEATS): neuroimaging review and genetics update.

Pediatric radiology
2026

Two-Stage Surgical Management of Intramedullary Holocord Astrocytoma in an Adult: A Case Report and Literature Review.

Current oncology (Toronto, Ont.)
2026

A rare early-onset bilateral renal cysts, focal seizures in a 1-year-old male with tuberous sclerosis and No mutation identified.

Oxford medical case reports
2026

From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas.

Cellular and molecular neurobiology
2026

The diagnostic value of cortical high-flow sign combined with cystathionine on 1H-MRS for prediction of 1p/19q-codeletion status in IDH-mutant adult-type diffuse glioma.

Neuroradiology
2026

Decoding the intricacy of insular glioma-lenticulostriate artery relationship: Results from a prospective comparative study of pre and postoperative magnetic resonance angiographic evaluation.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2025

Secondary exophytic glioblastoma of the cerebellopontine angle: a case report and review of the literature.

Frontiers in oncology
2026

Glioma chemotherapeutic resistance is tied to membrane electrophysiological properties and glycosylation.

Bioengineering &amp; translational medicine
2025

Radiation-induced sarcoma after glioma resection in patients with Li-Fraumeni syndrome: illustrative cases.

Journal of neurosurgery. Case lessons
2026

Desmoplastic infantile ganglioglioma/astrocytoma: Expanding the molecular and morphological spectrum with a novel BRAF fusion.

Neuro-oncology advances
2025

Consequences of Hypoxic Events, Necrosis, and Microvascular Density, in Astrocytoma IDH-Mutant, CNS WHO Grade 4.

Medical sciences (Basel, Switzerland)
2026

Time-intensity Profiles and T1-corrected Arterial Transit Time from Multi-delay Pseudo-continuous ASL with a Variable-TR Scheme for the Characterization of Adult-type Diffuse Glioma.

Clinical neuroradiology
2026

Pediatric High-Grade Astrocytoma With Piloid Features: A Comprehensive Literature Review.

Pediatric blood &amp; cancer
2026

Spinal deformity following surgery for paediatric intramedullary spinal cord tumours.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors.

Acta neuropathologica
2026

Autophagy-Cholesterol Axis Remodeling Supports Malignant Progression and Chemoresistance in Glioma.

bioRxiv : the preprint server for biology
2026

Association of CDKN2A/B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma.

Annals of clinical and translational neurology
2026

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.

JCO precision oncology
2026

Interleukin-9 Regulates NF-kB-Mediated Activation of Astrocytes in Multiple Sclerosis Brain.

Neurology(R) neuroimmunology &amp; neuroinflammation
2025

[Pilocytic astrocytomas with aggressive clinical course: a single-center experience].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2025

[Differential diagnosis of high-grade astrocytic gliomas based on CD44, SOX2, and CIRBP gene expression analysis].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2025

Extremely Long-Term Glioblastoma Survival (Ten Years): A Possible Role of Immune Modulation From Pre-existing Diseases.

Cureus
2025

Spectrum of spinal cord space occupying lesions: An observational perspective from Pakistan.

Pakistan journal of medical sciences
2025

Pilocytic Astrocytoma: An institutional perspective over the last decade.

Pakistan journal of medical sciences
2026

SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of Telomeres.

Neuro-oncology
2025

Molecular Characterization of Adult-Type Lower-Grade Glioma (WHO Grade 1-3) with Targeted Next-Generation Sequencing: A Retrospective, Single-Institution Experience.

Journal of clinical medicine
2025

Hypoxia-Driven Functional Conversion of CAPE: From Anti-Inflammatory to Pro-Tumorigenic Action in the Human Astrocytoma Cell Line CCF-SSTG1.

Molecules (Basel, Switzerland)
2026

Differences in Executive Functioning Between Patients with IDH1-Mutant Oligodendroglioma and Astrocytoma Before and After Surgery.

Cancers
2025

Behavioral Changes and Refractory Hypertension as the First Manifestations of Anaplastic Astrocytoma: A Case Report.

Cureus
2026

Permeation of small extracellular vesicles across a human blood-brain barrier transwell model remains below particle detection limits, even under oxygen/glucose deprived conditions.

Tissue barriers
2026

T2/FLAIR Mismatch Subregion as an Independent Prognostic Biomarker in IDH-Mutant and 1p/19q Noncodeletion Astrocytoma.

AJNR. American journal of neuroradiology
2026

Fluoroscopic C2 selective nerve root block enabled with CT angiogram.

Interventional pain medicine
2026

Circumscribed low-grade astrocytoma with a synchronous occipital lesion of uncertain pathology in an adolescent with T-cell lymphoblastic lymphoma.

BMJ case reports
2025

Unsupervised learning of metabolic fingerprints from 3D magnetic resonance spectroscopic imaging enables glioma subtype classification.

Neuro-oncology advances
2026

Multifocal anaplastic astrocytoma mimicking primary central nervous system lymphoma: A case report.

Medicine
2026

[Polymorphous low-grade neuroepithelial tumor of the young: a molecular pathological study].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2025

Atraumatic Shoulder Dislocation Revealing a Brain Tumor: A Case Report.

Cureus
2025

PRE-SURGERY BLOOD CELL RATIOS AND SURVIVAL IN PATIENTS WITH MALIGNANT GLIOMAS.

Experimental oncology
2026

Identification of aryl hydrocarbon receptor as a functional target that enhances astrocytic ApoE secretion.

Cell chemical biology
2026

A congenital infant-type hemispheric glioma case with EML4::ALK fusion.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2025

Noninvasive MGMT-promotor methylation prediction in high grade gliomas using conventional MRI and deep learning-based segmentations.

Frontiers in neuroscience
2025

Treatment differences in IDH-wildtype glioma - the impact of surgery and adjuvant therapy.

Journal of neuro-oncology
2025

New candidate gene mutations in astrocytoma with seizures.

Scientific reports
2025

Functionalized Carbon Dots from Bio-Based Precursors as Promising Fluorescent Probes for Cancer Cell Imaging.

International journal of molecular sciences
2025

Tumefactive Demyelinating Lesion Mimicking Low-Grade Astrocytoma with a T2/FLAIR Mismatch Sign: A Case Report and Review of the Literature.

Diagnostics (Basel, Switzerland)
2025

Single-cell and spatial transcriptome sequencing analysis reveals characteristics of a unique subpopulation in high-grade IDH-mutant astrocytoma.

Cellular oncology (Dordrecht, Netherlands)
2025

Distinct molecular profiles characterize the spontaneous growth rate of IDHmt low-grade astrocytomas and oligodendrogliomas.

Neuro-oncology
2025

Presenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification.

Neuro-oncology practice
2025

Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study.

Neuro-oncology practice
2025

Unusual localization of pilocytic astrocytoma at the foramen of Monro mimicking a colloid cyst: a case report and literature review.

Frontiers in oncology
2026

Neoadjuvant PD1 blockade with laser interstitial thermal therapy for recurrent high-grade glioma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2026

Staining the Invisible: Immunohistochemistry for Early Detection of Mismatch Repair Deficiency in Pediatric High-Grade Brain Tumors.

Pediatric blood &amp; cancer
2025

The contribution of methylation profiling in neuropathological diagnosis of central nervous system tumors in children, adolescent and young adults.

Pathologica
2025

Suprasellar desmoplastic infantile astrocytoma and ganglioglioma: an institutional series report and a clinical summary of this rare tumor.

Frontiers in oncology
2025

Cerebellar pilocytic astrocytoma in a patient with autism spectrum disorder and psychotic symptoms: a case report.

BMC psychiatry
2026

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

The Lancet. Oncology
2025

Stimulating the Human Olfactory Bulb to Evoke Smell Perception: A Case Report from Awake Brain Surgery.

ORL; journal for oto-rhino-laryngology and its related specialties
2026

Detection of Tumor-Specific Variants in CSF of Children With Brain Tumors, Including Low-Grade and Cytology-Negative Cases.

Pediatric blood &amp; cancer
2025

The Fourth Ventricle, A Rare Location for Subependymal Giant Cell Astrocytoma (SEGA): A Rare Case Report.

Clinical case reports
2025

Functional analysis of telomere maintenance mechanisms is more informative than immunohistochemistry for ATRX mutation interpretation in Gliomas.

Acta neuropathologica communications
2026

Microfluidic biosensors and devices for brain tumor diagnosis and monitoring.

Clinica chimica acta; international journal of clinical chemistry
2025

Bridging Radiology and Pathology: ATRX Loss and T2-FLAIR Mismatch as Early Diagnostic and Prognostic Markers in Diffuse Gliomas.

JPMA. The Journal of the Pakistan Medical Association
2026

Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort Study.

Neurology
2025

Benchmarking nazionale della sopravvivenza per stadio alla diagnosi dei tumori infantili in Italia (BENCHISTA-ITA): protocollo di studio.

Epidemiologia e prevenzione
2025

Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant Glioma.

Neuro-oncology
2025

Biopsy and laser ablation as a treatment strategy for pediatric brain incidentalomas.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2025

Combined Hamartoma of the Retina and Retinal Pigment Epithelium: A Literature Review and Case Series.

Cureus
2026

[Vorasidenib as monotherapy in grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation].

Bulletin du cancer
2025

Unpredictable Evolution of Pilocytic Astrocytoma in Adults: A Case Series and Diagnostic Challenges.

The American journal of case reports
2025

Diffuse astrocytoma presenting with parkinsonism and gliomatosis-like infiltration.

The New Zealand medical journal
2025

Expression and Functional Role of the P2X7 Receptor in Glioma Models and Tissues: A Systematic Review.

Cancers
2025

Next-Generation Sequencing Reveals a Diagnostic and Prognostic Role of the TP53 R273C Mutation in Lower-Grade, IDH-Mutant Astrocytomas.

International journal of molecular sciences
2025

Free water elimination tractometry reveals local and remote white matter alterations in diffuse gliomas.

Journal of neuro-oncology
2025

Single cell spatial profiling of the matrisome identifies region-specific adhesion and signaling networks in glioblastoma.

Communications biology
2025

Unexpected [18F] Fluciclovine Uptake in Pilocytic Astrocytoma: A Pediatric Case Report.

Clinical nuclear medicine
2025

[Molecular Genetic Analysis of Childhood Brain Tumors].

No shinkei geka. Neurological surgery
2025

PCR-based detection of Epstein-Barr virus in brain tumors of Iraqi patients with grade I-IV astrocytomas.

Human antibodies
2025

Prognostic and predictive determinants in high-grade gliomas: integrating tumor-intrinsic biology with patient and system-level factors.

Frontiers in neurology
2025

How to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis.

Frontiers in oncology
2026

An atypical presentation of a pleomorphic xanthoastrocytoma in a 66-year-old woman, a case report.

Radiology case reports
2025

Mismatch Repair Deficiency in Gliomas: A Rare Insight into Microsatellite Instability and Its Diagnostic Implications.

Asian journal of neurosurgery
2025

Stereotactic radiosurgery for subependymal giant cell astrocytoma: Multi-institutional retrospective analysis of clinical and radiological outcomes.

Neurosurgical review
2026

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2025

Clinical and molecular characteristics and prognostic factors of diffuse astrocytoma, IDH-wildtype, not elsewhere classified.

Journal of neuro-oncology
2025

Development and validation of a multi-modal MRI-based deep learning framework for differentiation of intraspinal tumors (ISMF-Net).

EClinicalMedicine
2025

Case Report: FGFR1 mutation and massive chromosome loss drive malignant transformation of low-grade gliomas.

Frontiers in oncology
2025

Isocitrate Dehydrogenase-Mutant WHO Grade 4 Astrocytoma with BCOR Alteration: Case Report.

Case reports in oncology
2025

Wounded Glioma Syndrome: A Case Report With Narrative Review.

Cureus
2026

Differential opioid receptor expression and biochemical coupling profiles on glia.

Biochemical pharmacology
2025

Evaluating the functional status of somatostatin receptors by 99mTc-octreotide scan in patients suffering from primary brain tumors.

Revista espanola de medicina nuclear e imagen molecular
2025

Precise diagnosis of pediatric posterior cranial fossa neoplasms based on 2.5D MRI deep learning.

Frontiers in oncology
2025

A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group.

The Lancet. Oncology
2025

Intraoperative Language mapping in a Japanese-English-French trilingual patient with a left Temporal lobe glioma: a case report.

Brain structure &amp; function
2025

Optical express-biopsy of gliomas using macroscopic fluorescence lifetime imaging.

Biomedical optics express
2025

Ten years of pediatric low-grade glioma care in Kenya: Outcomes, progress, and gaps toward achieving global childhood cancer equity.

Neuro-oncology pediatrics
2025

[Molecular subtype-driven surgical concepts and clinical application in gliomas].

Zhonghua wai ke za zhi [Chinese journal of surgery]
2025

Distinguishing IDH-mutant astrocytomas from IDH-wildtype glioblastomas using qualitative and quantitative MRI features: a WHO CNS5 study.

BMC medical imaging
2025

Circumscribed Pilocytic Astrocytoma Including Pilomyxoid and Intermediate Pilomyxoid Variants - A Single Institutional, Retrospective Study.

Indian journal of surgical oncology
2026

Pediatric Diffuse Low-Grade Gliomas: Radiology, Symptoms, Treatment, and Molecular Pathways.

Neuroimaging clinics of North America
2026

Clinical potential of [18F]FET PET in patients with circumscribed astrocytic glioma.

European journal of nuclear medicine and molecular imaging
2025

Designing a web-based platform for dynamic estimation of individualized conditional survival in grade 3 gliomas.

Discover oncology
2025

Neuro-ophthalmic clues affecting the surgical approach to a brain tumor: the case of a craniopharyngioma masquerader.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2025

Gliadel use in a pregnant patient with malignant glioma: a case report.

Frontiers in oncology
2025

Imaging features of high-grade astrocytoma with piloid features: A single center case series.

The neuroradiology journal
2025

Epidemiological characteristics and prognostic factors of high-grade brainstem glioma for all ages and the establishment of a nomogram.

Translational cancer research
2025

Patient-Reported Outcomes, Neurocognitive Functioning, and Oncologic Results of Pencil-Beam-Scanning Proton Beam Therapy for CNS WHO G2 and G3 IDH1-Mutant Diffuse Adult Glioma: A Single Institution Experience.

International journal of radiation oncology, biology, physics
2025

Added value of sodium MRI in multiparametric MRI for WHO grade II astrocytoma surveillance during "watchful waiting": initial experience.

Radiologie (Heidelberg, Germany)
2025

MRI-based prediction of DNA methylation grade in IDH-mutant astrocytomas using qualitative imaging features and tumor volumetrics.

Neuroradiology
Ver todos os 4.802 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Astrocitoma.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Astrocitoma

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. TERT Promoter Methylation in Glioblastoma and its Paradoxical Association with Upregulated Gene Expression.
    Neurology India· 2026· PMID 41817063mais citado
  2. High-Grade Astrocytoma With Piloid Features: An Aggressive Clinicogenomic Entity Distinct From Pilocytic Astrocytoma.
    Journal of Korean medical science· 2026· PMID 41807027mais citado
  3. Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.
    Journal of neuropathology and experimental neurology· 2026· PMID 41802222mais citado
  4. Central Precocious Puberty and Optic Pathway Glioma in Children with Neurofibromatosis 1: Associations with Tumor Location, Vision, and Treatment.
    The Journal of pediatrics· 2026· PMID 41780670mais citado
  5. Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.
    Nature communications· 2026· PMID 41748622mais citado
  6. Sudden death from a clinically silent right insular infarct in a patient with prior left insular astrocytoma.
    J Neuropathol Exp Neurol· 2026· PMID 41991163recente
  7. [Features of brain involvement in tuberous sclerosis patients in the Republic of Bashkortostan].
    Zh Nevrol Psikhiatr Im S S Korsakova· 2026· PMID 41984558recente
  8. CNS tumor type prevalence according to age group: an analysis of 21,000 cases confirmed by methylation profiling, with a focus on adolescents and young adults.
    Neuro Oncol· 2026· PMID 41978543recente
  9. Gasdermin as a Molecular Signature and Predictor of Adult-Type Diffuse Glioma Severity and Grading.
    J Clin Med· 2026· PMID 41977007recente
  10. Microsurgical Resection of Subependymal Giant Cell Astrocytoma: Single-Center Retrospective Analysis and Meta-Analysis.
    Neurosurgery· 2026· PMID 41972772recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:94(Orphanet)
  2. MONDO:0021636(MONDO)
  3. GARD:12928(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q177755(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Astrocitoma
Compêndio · Raras BR

Astrocitoma

ORPHA:94 · MONDO:0021636
Prevalência
1-9 / 100 000
CID-10
C71 · Neoplasia maligna do encéfalo
Ensaios
13 ativos
Medicamentos
11 registrados
Início
All ages
Prevalência
2.5 (Europe)
MedGen
UMLS
C0004114
Repurposing
2 candidatos
carmustineDNA alkylating agent|DNA inhibitor
temozolomideDNA alkylating agent
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades